Table 1 Patient´s characteristics at baseline and before re-irradiation
From: Re-irradiation of recurrent pediatric ependymoma: modalities and outcomes: a twenty-year survey
Patient | Age at diagnosis (years) | Tumor location | Histology (grade) | Treatment at diagnosis | Chemotherapy before RT1 | Surgery before RT1 | Radiotherapy 1 (dose Gy) | Pattern of failure | Lesion | TTP 1 (months) |
|---|---|---|---|---|---|---|---|---|---|---|
1 | 6.6 | IT | AE (III) | No RT | Yes | GTR | FFRT (54) | Local | S | 50 |
2 | 1.1 | IT | AE (III) | No RT | Yes | GTR | FFRT (57.6) | Local | S | 34 |
3 | 1.6 | IT | AE (III) | RT | No | GTR | FFRT (56) | Local | S | 31 |
4 | 7.7 | IT | AE (III) | RT | No | GTR | FFRT (54) | Local | M | 43 |
5 | 7.6 | ST | AE (III) | RT | No | GTR | FFRT (54) | Local | S | 12 |
6 | 2.0 | ST | AE (III) | No RT | Yes | GTR | FFRT (54) | Local | S | 18 |
7 | 3.7 | IT | AE (III) | No RT | Yes | GTR | FFRT (54) | Local | S | 26 |
8 | 11.2 | IT | AE (III) | RT | Yes | STR | FFRT (59.4) | Local | M | 33 |
9 | 11.4 | ST | AE (III) | RT | No | GTR | FFRT (54) | Local | S | 11 |
10 | 10.3 | IT | AE (III) | RT | No | GTR | FFRT (54) | Local | S | 61 |
11 | 2.4 | ST | AE (III) | No RT | Yes | GTR | FFRT (54) | Local | S | 13 |
12 | 5.2 | ST | AE (III) | No RT | No | GTR | FFRT (54) | Local | M | 10 |
13 | 7.6 | IT | AE (III) | RT | No | GTR | FFRT (54) | Local | S | 18 |
14 | 2.7 | IT | E (II) | RT | Yes | STR | FFRT (50.4) | Local | S | 86 |
15 | 2.2 | IT | E (II) | No RT | Yes | NS | SRS (18) | Local | S | 36 |
16 | 0.4 | IT | AE (III) | No RT | Yes | GTR | FFRT (48.6) | Metastatic | S | 65 |
17 | 2.6 | IT | AE (III) | RT | No | GTR | FFRT (59.4) | Metastatic | S | 12 |
18 | 0.8 | IT | AE (III) | No RT | Yes | GTR | FFRT (54) | Metastatic | S | 3 |
19 | 9.8 | IT | AE (III) | RT | No | GTR | FFRT (54) | Metastatic | S | 45 |
20 | 6.1 | IT | AE (III) | RT | No | STR | FFRT (55) | Metastatic | S | 7 |
21 | 14.6 | IT | AE (III) | RT | No | GTR | FFRT (54) | Metastatic | S | 10 |
22 | 5.5 | IT | AE (III) | RT | No | STR | FFRT (50) | Metastatic | S | 4 |
23 | 6.3 | IT | AE (III) | RT | No | GTR | FFRT (59.4) | Metastatic | S | 14 |
24 | 4.0 | IT | AE (III) | No RT | Yes | STR | FFRT (55) | Metastatic | S | 4 |
25 | 6.8 | IT | E (II) | RT | No | GTR | FFRT (54) | Metastatic | S | 8 |
26 | 17.1 | SP | AE (III) | RT | No | STR | FFRT (54) | Metastatic | M | 2 |
27 | 8.9 | IT | E (II) | RT | No | STR | FFRT (55) | Metastatic | S | 100 |
28 | 3.7 | IT | E (II) | RT | No | GTR | FFRT (50.4) | Metastatic C | M | 13 |
29 | 7.3 | SP | E (II) | RT | No | STR | FFRT (41.4) | Metastatic C | M | 8 |
30 | 1.8 | IT | AE (III) | RT | No | GTR | FFRT (54) | Metastatic | M | 11 |
31 | 16.1 | SP | E (II) | RT | Yes | STR | FFRT (55) | Metastatic | M | 25 |
32 | 6.6 | IT | AE (III) | RT | Yes | STR | FFRT (54) | Metastatic | S | 15 |